Accessibility Skip to:
  • Accessibility Policy
  • Main Content
  • Main Menu
  • Contact

  • -A: Font Smaller
  • +A: Font Larger
  • Reset Font
  • High Contrast
  • Low Contrast
  • Reset Contrast
History:
You are here:
  • Grand Challenges Canada
  • >
  • Innovations
  • >
  • 0226-01
  • Français
  • Get to Know Us
    • Who We Are
    • Co-CEOs
    • Governance
    • Accountability
    • The Team
    • Partnerships
    • Career Opportunities
    • Service Opportunities
    • Contact Us
  • Learn What We Do
    • What We Do
    • Global Health
    • Humanitarian
    • Indigenous
    • Transition To Scale
    • Innovative Financing
    • Innovations & Results
    • Annual Report
  • Apply for Funding
    • Funding Opportunities
    • Innovator Resources
    • Gender Equality Portal
  • Get Informed
    • News and Media
    • Blog
    • Publications
    • Subscribe
    • Photos and Videos
Grand Challenges Canada

Bold Ideas with Big Impact®

Browse our Innovations and Results
  • Get to Know Us
    • Who We Are
    • Co-CEOs
    • Governance
    • Accountability
    • The Team
    • Partnerships
    • Career Opportunities
    • Service Opportunities
    • Contact Us
  • Learn What We Do
    • What We Do
    • Global Health
    • Humanitarian
    • Indigenous
    • Transition To Scale
    • Innovative Financing
    • Innovations & Results
    • Annual Report
  • Apply for Funding
    • Funding Opportunities
    • Innovator Resources
    • Gender Equality Portal
  • Get Informed
    • News and Media
    • Blog
    • Publications
    • Subscribe
    • Photos and Videos
  • Accessibility
  • Contact
  • Français

Home » Innovations » 0226-01

Heat shock drugs for malaria: reversing resistance

FacebookTwitterLinked In

Start Date: 01/04/2013- End Date: 30/09/2014


Project Lead(s): Dylan Pillai

Issue

Close to 600,000 people die from malaria infection annually, with Sub-Saharan Africa suffering the brunt of the mortality.

A contributing factor is the emergence of antimalarial resistance to the best drugs available, including artemisinin and its partner drugs, such as piperaquine.

Solution

A bold approach has been proposed to identify novel agents that reverse resistance to mainstay antimalarial drugs, such as artemisinin.

These new reversal agents will target heat shock protein 90 that can restore antimalarial activity.

The team sought to identify an antimalarial compound derived from a West African traditional medicine demonstrated in pre-clinical trials to have potent activity.

It is hoped this compound (harmine derivative 21A), which targets heat shock protein 90 (Hsp90), can forestall the rising tide of artemisinin resistance.

Outcome

This modification of harmine (21A) showed the capacity to inhibit Hsp90, kill malaria parasites in the test tube, and prolong survival of mice when used in combination with artemisinin, without exhibiting untoward toxicity.

The plan is to conduct further trials with 21A-like derivatives after patent protection is achieved.

Results of this work were discussed in conference presentations and were being prepared for publication. 

Stay in touch with this innovator

  • Organization Website
  • Network Website
  • Innovation Overview
    Program

    Stars in Global Health

    Institution

    University of Calgary

    Institution Country

    Canada

    Implementation Country

    Cameroon

    Implementation Region

    North America, Sub-Saharan Africa

    Priority

    Infectious Diseases, Malaria

    Platform

    Drug

Grand Challenges Canada’s programs are primarily undertaken with the financial support of the Government of Canada provided through Global Affairs Canada.

Government of Canada
  • Fluxx Technical Support
  • Privacy Policy
  • Website Legal Terms and Disclaimer